There has beell considerable recent interest ill the treatment of anginla pectoris witlh iproniazid. In this paper the results of a careful double-blind study of its effect are evaluated.
shown it to be capable of reversing apathy, astlhenia, anorexia, and depression in doses ranging up to 300 nig. per day.2 However, doses of this magniitude have also produced psychoses, both transient and permanent. [5] [6] Investwration into the mode of action of this drug by Zeller and his group established it to be a potent inhibitor in vivo and in vitro of the enzyme monoamine oxidase.7 9 Shore and his co-workers found this enzyme to be iimvolved in the metabolism of the catecholamiiines-norepinephrine and serotonin-in both in vivo and in vitro experiments.10 These catecholamines, moreover, may be of prime importance in the chemical mediation of the brain stem, especially of the centers for autonomic control.11 Based on these findings, the hypothesis has been advanced that the changes induced in catecholamine metabolism could be responsible for the antidepression action of iproniazid. 12 Recently Cossio, m3' 14 in Argentina, and Cesarmain , 1 -17 in Mexico, reported remark- able amelioratiomi of the paimi ill the angina pectoris syndrome secondary to isehemic heart disease. Their patients had classic symptomnatology, namely, pain upon exertion relieved spontaneously by rest and nitroglycrein, though not with uniform success. Moreover, all had abnormal patterns in electrocardiograms at rest and after exercise.
Fifty milligrams of iproniazid were givemi 3 times daily for 3 weeks, and then the dose was reduced with symptomatic improvement.
The results were impressively satisfactory, paimn being reduced for as long as 6 months of therapy. Reduction in dosage did not abolish this beneficial effect, but on discontinuance of treatnment pains recurred within days and up to 1 month. The course of the illness itself remained unmodified in that the abnormal electrocardiograms remained umlchallged. Cesarman The experiences of these investigators have emphasized that iproniazid can be "very helpful in angina pectoris, but must be used with caution because of toxic side reactions, ''23 yet was also described as "the first promising drug in a whole professional career of nearly four decades. " 24 We considered that the initial promise of this drug could add a new dimension to the treatment of ischemic heart disease, and therefore, that further delineation of its utility and safety at a daily dose of 50 mg. or less was warranted. In our opinion, such an experiment could be conducted accurately only under the most stringent conditions. Fortunately, there are now available technics of pharmacologic investigation that make possible accurate assessment of a given symptomatic therapy. Of these the double-blind method is the most successful. Katz recommends that in a well-controlled double-blind experiment each patient in the series be subjected also at several different times to both the drug and placebo. This precaution is especially important when the effect on anginal pain is tested.25
METHODS AND MATERIAL
Using this recommendation for our model, we set up a double-blind study in our cardiac clinic, where a group of closely observed cardiac patients whose diagnoses of ischemic heart disease with angina pectoris had been confirmed over a long period of treatment. Moreover, they had received most of the well-known therapeutic agents, which could serve as a comparison with the response to any new medication. All had had complete histories and physical examinations. The laboratory studies included a complete blood count, urinalysis, electrocardiogram, chest x-ray, blood glucose, and blood urea nitrogen. Individuals previously treated for angina pectoris were re-interviewed to reestablish the diagnosis. Only.patients with anterior chest pain following exertion or emotional upset, which was relieved within 20 minutes by rest, with or without sublingual nitroglycerin, were included in the study. All previous medications and treatment, i.e., sedation, digitalis, nitrites, ataractics, and diuretics including chlorothiazide were continued unchanged.
The patients were seen at 2-week intervals and interviewed according to a question sheet that ineluded presence of angina, the number of attacks of pain and of nitroglycerin tablets used, dyspnea, edema, appetite, strength, well-being, and sleep habits. The responses called for were limited to "better," "unchanged," or "worse," and reports of unpleasant reactions. With each visit, physical examinations were performed consisting of a blood pressure recording, stethoscopic examination of heart and lungs, weight, and inspection for peripheral edema. Laboratory examinations included a serum bilirubin and cephalin flocculation test at each visit to detect any hepatic toxicity, and, when possible, a final electrocardiogram at the conclusion of the study.
The tablets used were identically prepared and bottled. They were labeled "A," "B," "C," and "D." Two of these were placebo and 2 were iproniazid, and the key was withheld from all the investigators until completion of the experiment. The patients were placed on medication in random fashion according to the week in which they were taken into the project. Those seen the first week were given "A," those the second week were begun on "B" and so on for the third and fourth week. The sequence then began over again with "A" for those begun on the fifth week. Patients were followed through in alphabetic sequence with a change in letter each month. Thus, the patient begun with "C," followed up with "D" was then placed on "A" and finally "B." The dose was 1 25-mg . tablet twice daily unless it was reduced for reasons of intolerance. At the conclusion of the experiment, the key was broken and the results were analyzed. The investigation was then continued, with 25-mg. iproniazid tablets administered daily to 11 patients who remained cooperative. We began the study with 35 patients, but were able to conclude our observations successfully, for purposes of analysis, in a total of 23. They ranged in age from 52 to 85 years; 3 were Negroes, and the remaining were white subjects; 8 were male, and 15 were female. Nineteen received all 4 trials in sequence. Of the remaining 4, 1 received 1 placebo and 1 iproniazid trial; and of the last 3, 2 had 2 iproniazid and 1 placebo trial, while the last had 1 iproniazid and 2 placebo trials. Eight began the trial sequence with "A," 6 with "B," 5 with "C," and 4 with "D."
The greater number of the 12 patients who failed to complete the study were dropped for lack of cooperation and failure to keep appointments as scheduled. Two who refused to permit the serum bilirubin and cephalin flocculation tests were dropped. Eighteen had previous or current cardiac decompensation, and the heart was enlarged at x-ray examination in 16. Two had normal resting electrocardiograms, but 1 demonstrated an unequivocally positive electrocardiogram after an exercise tolerance test. Seven had had previous myocardial infaretions and 2 more had noted previous suspicious, but not completely confirmed episodes. The drugs previously used were continued. Seventeen patients required daily maintenance digitalis, 10 required oral or parenteral diuretics, and 4 were receiving reserpine for hypertensive therapy. All 23 were taking sublingual nitroglycerin tablets in amounts ranging from 2 to 140 tablets per week. Five others took long-acting nitrates, 3 had daily theophylline, and another took meprobamate to ameliorate the painful episodes. In summary, all patients had confirmed isehemic heart disease, due to arteriosclerotic heart disease that was complicated by hypertension in nearly half. All but one had electrocardiographic abnormalities, and most showed evidences of advanced heart disease manifested by cardiac enlargement and congestive heart failure.
Method of Evacuation
To evaluate the results we followed a modified technic of classification, used by Blumgart et al. 26 for analysis of the response to thyroid irradiation by similar patients with angina pectoris. In this series, we have also included those who had to discontinue the trial medication due to severe side effects.
The fortuitous selection of drugs which presented first the placebo, then 2 months of iproniazid with a final month of placebo, producec 2 consecutive months of active treatment followed abruptly by a replacement by the placebo. With the initial randomization of patients, only those 5 begun with 
RESULTS
The detailed results of the trials are tabulated in tables 2 to 6. The increasing number of reactions with prolonged use of the drug emphasized the need to determine its effectiveness at the lower dose level of 25 mg. per day. Eleven patients were placed on this amount and followed for at least 1 month further. Nine of them re- 
